A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Eligibility criteria
Qualifiers
Patients aged ≥ 30 years old with exertional dyspnea (NYHA II and III) and LVEF ≥50%
BMI ≥ 30
New diagnosis of HFpEF based on RHC at baseline (elevated PCWP at rest and/or during exercise)
Primary cardiomyopathy or pericardial disease or ≥ moderate valvular disease
Disqualifiers
None
Trial design
Treatments tested in this trial
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
Treatment groups
35 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov